Skip to main content

Table 1 Demographic, clinical and laboratory data of the studied subjects

From: Malondialdehyde and superoxide dismutase levels in patients with epilepsy: a case–control study

  Epileptic group (n = 62) Controls group (n = 62) test p
Age (years)
 Mean ± SD 27.98 ± 6.44 26.63 ± 6.06 t = 1.207 0.230
 Range 18.0–43.0 19.0–39.0
Sex No % No %   
 Male 36 58.1 35 56.5 χ2 = 0.033 0.856
 Female 26 41.9 27 43.5
Age of onset
 Mean ± SD 17.85 ± 4.64   
Disease duration (years)
 Mean ± SD 13.11 ± 8.19   
Seizure type No %    
 Focal 21 33.9   
 Generalized 41 66.1   
Seizure control No %    
 Controlled 26 41.9   
 Uncontrolled 36 58.1   
Seizure frequency of uncontrolled patients No %    
 More than once /month 10 27.8   
 Once/ 1–2 months 14 38.9   
 Once/ 3–4 months 7 19.4   
 Once/ 5–6 months 5 13.9   
Type of therapy No %    
 Monotherapy 27 43.5   
 Polytherapy 35 56.5   
MDA (nmol/ml)
 Mean ± SD 5.83 ± 1.46 4.80 ± 0.62 5.075 < 0.001*
SOD (U/ml)
 Mean ± SD 7.59 ± 0.85 11.98 ± 1.39 21.228 < 0.001*
  1. t Student t test, χ2 Chi square test, p p value for comparing between the studied groups, MDA malondialdehyde, SOD superoxide dismutase, * significant